PIRS News and Press, Pieris Pharmaceuticals Inc. From 07/20/20

FDA requested a confirmatory laboratory-based in-use and compatibility study before enrolling new patients Currently-enrolled patients may continue to receive PRS-343 In its telephonic communication, FDA did not cite any adverse events in connection with its request Company ...

BOSTON, MA / ACCESSWIRE / June 8, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer, and other diseases, announced today that due to t...

BOSTON, MA / ACCESSWIRE / May 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, announc...

Pieris Pharmaceuticals, Inc. (PIRS) Q1 2020 Earnings Conference Call May 11, 2020 8:00 AM ET Company Participants Tom Bures – Vice President of Finance Steve Yoder - President and Chief Executive Officer Ingmar Bruns – Senior Vice President and Head of Clinical Deve...

Pieris Pharmaceuticals (NASDAQ: PIRS ): Q1 GAAP EPS of -$0.07 beats by $0.08 . More news on: Pieris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Company to Host an Investor Conference Call on Monday, May 11, 2020 at 8:00 Am Edt BOSTON, MA / ACCESSWIRE / May 11, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ...

BOSTON, MA / ACCESSWIRE / May 4, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced tha...

NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March 26, March 31, and April 2, 2020, featuring leading companies from the life sciences indus...

BOSTON, MA / ACCESSWIRE / March 23, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer, and other diseases, today announced a...

IDEAYA Biosciences (NASDAQ: IDYA ) initiated with Buy rating and $12 (192% upside) price target at Roth Capital. More news on: IDEAYA Biosciences, Inc., Menlo Therapeutics Inc., Amarin Corporation plc, Healthcare stocks news, Stocks on the move, , Read more ...